* Coverage criteria: For the treatment of type 2 diabetes in combination with metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control. Patients intolerant to glyburide may try another sulfonylurea (e.g., gliclazide, which is available through the PharmaCare Special Authority program). Special Note: Coverage will be provided for either semaglutide or an eligible dipeptidyl peptidase-4 (DPP-4) inhibitor for patients that have coverage for DPP-4 inhibitor, approval for semaglutide coverage will result in discontinuation of coverage for DPP-4 inhibitor patients intolerant to a sulfonylurea may be considered for coverage. * Coverage criteria: As part of treatment for type 2 diabetes mellitus after inadequate glycemic control on maximum tolerated doses of dual therapy of metformin and a sulfonylurea or dual therapy of metformin and an insulin.
Special authorization may be granted for 24 months.
#OZEMPIC COPAY CARD TRIAL#
* Coverage criteria: As add-on therapy for the treatment of type 2 diabetes in patients with intolerance to and/or inadequate glycemic control on: a sufficient trial (i.e., a minimum of 6 months) of metformin, AND a sulfonylurea, AND for whom insulin is not an option OR for whom these products are contraindicated. RAMQ is an official mark of the Régie de l’assurance maladie du Québec. Ineffectiveness means the non-attainment of the value of glycated hemoglobin (HbA1c) adapted to the patient.
Authorization is given for a weekly maximum dose of 1 mg. Quebec (RAMQ) Exceptional Medication: For the treatment of type-2 diabetic persons, in association with metformin, where a sulfonylurea is contraindicated, not tolerated, or ineffective.
Other relevant warnings and precautions relating to intramuscular administration, CV effects (increased heart rate PR interval prolongation), hypoglycemia with concomitant use of insulin secretagogues or insulin, use with other incretin drugs, hepatic insufficiency, pancreatitis, hypersensitivity, diabetic retinopathy (in patients with history of disease, monitor for progression), and renal impairment (severe GI adverse reactions warrant monitoring of renal function use in end-stage disease).A serious warning on risk of thyroid C-cell tumours.Contraindications in personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN 2), and pregnancy or breastfeeding.Please consult the Product Monograph at OzempicPM-E.ca or basal insulin with metformin, when diet and exercise plus basal insulin with metformin do not achieve adequate glycemic control.metformin or a sulfonylurea and a sodium-glucose cotransporter 2 inhibitor (SGLT2i), when diet and exercise plus metformin or a sulfonylurea, in addition to an SGLT2i, do not achieve adequate glycemic control.metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control.metformin, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control.diet and exercise in patients for whom metformin is inappropriate due to contraindication or intolerance.Ozempic ® (semaglutide injection) is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with: 2
0 kommentar(er)
